Zeltia Group: Report at 31 March 2005

Madrid (ots/PRNewswire) - PharmaMar:

- Zalypsis: this is PharmaMar's fifth compound to reach clinical development.

- Aplidin: commenced Phase II studies on prostate and bladder cancer.

- Yondelis: pivotal Phase III studies commenced on ovarian cancer patients.

NeuroPharma:

- Presented pre-clinical data at the 7th International Conference on Alzheimer's and Parkinson's Disease.

Other:

- Investment in R&D amounted to 8.9 million euro in the first quarter.

- Group short- and long-term debt was similar to December 2004.

- Net cash consumption was 3.8 million euro in the first quarter.

Rückfragen & Kontakt:

Isabel Lozano, CEO, PHARMAMAR, S.A., C/ Reyes, 1.Colmenar Viejo,
Madrid, Telephone +34-91-846-60-00; Catherine Moukheibir, Head of
Capital Market Strategy, ZELTIA, S.A., José Abascal, 2. Madrid,
Telephone +34-91-444-45-00; Ma. Luisa de Francia, CFO, ZELTIA, S.A.,
José Abascal, 2. Madrid, Telephone +34-91-444-45-00

OTS-ORIGINALTEXT UNTER AUSSCHLIESSLICHER INHALTLICHER VERANTWORTUNG DES AUSSENDERS | PRN0006